Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 642,343 shares, a growth of 780.2% from the April 15th total of 72,973 shares. Approximately 19.3% of the shares of the company are short sold. Based on an average daily volume of 18,420,264 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Investors Weigh In On Scinai Immunotherapeutics

An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC boosted its stake in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,630 shares of the company’s stock after purchasing an additional 17,031 shares during the quarter. Citadel Advisors LLC owned about 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 58.41% of the stock is owned by institutional investors.

Scinai Immunotherapeutics Price Performance

Shares of Scinai Immunotherapeutics stock traded down $0.03 on Wednesday, reaching $0.51. The stock had a trading volume of 131,571 shares, compared to its average volume of 10,320,994. Scinai Immunotherapeutics has a 1 year low of $0.45 and a 1 year high of $6.18. The company has a market cap of $1.79 million, a P/E ratio of -0.05 and a beta of 2.19. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.12. The business’s 50 day moving average is $0.64 and its two-hundred day moving average is $0.84.

Scinai Immunotherapeutics (NASDAQ:SCNI) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $3.80 earnings per share (EPS) for the quarter. The firm had revenue of $0.27 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Scinai Immunotherapeutics currently has a consensus rating of “Sell”.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.